Nektar Therapeutics | NKTR - Interest Expense On Debt


Nektar Therapeutics reported $9.77M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
Agios Pharmaceuticals USD 1.18B 4.3B Mar/2026
ALKERMES USD 20.89M 8.62M Mar/2026
Amgen USD 657M 4M Mar/2026
Baxter International USD 58M 14M Sep/2025
BioCryst Pharmaceuticals USD 14.14M 5.53M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
Bristol-Myers Squibb USD 411M 21M Mar/2026
Cara Therapeutics -89.64M 128.67M Dec/2025
Cipla INR 131.3M 9M Mar/2026
Dr.Reddys Laboratories INR 1.06B 113M Mar/2026
Eisai JPY 1.55B 117M Mar/2026
Eli Lilly USD 114.7M 134.3M Sep/2025
Esperion Therapeutics USD 22.64M 585K Dec/2025
Exelixis USD 23.4M 3.9M Sep/2023
Gilead Sciences USD 240M 15M Mar/2026
GlaxoSmithKline GBP 167M 21M Mar/2026
Grifols EUR 156.07M 31.46M Sep/2025
Halozyme Therapeutics USD 5.51M 597K Mar/2026
Incyte USD 569K 13K Mar/2026
Ionis Pharmaceuticals USD 17M 1000K Mar/2026
Ironwood Pharmaceuticals USD 8.74M 506K Dec/2024
Karyopharm Therapeutics USD 12.62M 1.24M Dec/2025
MacroGenics USD 4.89M 1.55M Mar/2026
Merck USD 479M 67M Mar/2026
Nektar Therapeutics USD 9.77M 3.75M Dec/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 343M 39M Mar/2026
Pfizer USD 671M 40M Mar/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sarepta Therapeutics USD 20.84M 13.28M Dec/2025
Takeda JPY 43.65B 79.98B Mar/2026
Teva Pharmaceutical Industries USD 216M 4M Mar/2026
Xencor USD 4.7M 2.65M Mar/2026